

Expression of the $\alpha 6 \beta 4$ Integrin by Squamous Cell Carcinomas and Basal Cell Carcinomas: Possible Relation to Invasive Potential?

KRISTIAN ROSSEN¹, KARIN K. DAHLSTRØM², ARTHUR M. MERCURIO³ and ULLA M. WEWER⁴

Departments of ¹Pathology and ²Plastic Surgery, University Hospital, Rigshospitalet, Copenhagen, Denmark, ³Laboratory of Cancer Biology, Deaconess Hospital, Harvard Medical School, Boston, USA and ⁴Laboratory of Molecular Biology, University Institute of Pathological Anatomy, Copenhagen, Denmark

We have studied the expression of $\alpha 6 \beta 4$ integrin, a carcinoma laminin receptor in ten squamous cell carcinomas (SCCs) and ten basal cell carcinomas (BCCs) of the skin in order to examine whether changes in $\alpha 6 \beta 4$ integrin expression may be related to invasive and metastatic potential. Monoclonal antibodies specific for each subunit were applied on cryosections, using a three step indirect peroxidase technique. In normal epidermis the basal cells expressed both the $\alpha 6$ and the $\beta 4$ subunits, and the expression was polarized against the basement membrane. In SCCs the expression of the $\alpha 6$ and the $\beta 4$ subunits paralleled each other, showing an increased intensity and loss of polarity. The BCCs, however, showed consistently decreased expression of both the $\alpha 6$ and the $\beta 4$ subunits. The results of our study, as well as those of other studies, support the assumption that the increase and depolarization of $\alpha 6 \beta 4$ integrin that occurs in SCCs might be related to the invasive properties of this tumour type. **Key words:** Invasion; Immunohistochemistry.

(Accepted September 20, 1993.)

Acta Derm Venereol (Stockh) 1994; 74: 101–105.

K. Rossen, Department of Pathology, University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.

Tumour invasion and metastasis depend, in part, on the ability of tumour cells to alter their adhesion to each other and to the extracellular matrix. Many studies on invasion and metastasis have highlighted the importance of tumour cell adhesion to laminin (1, 2). In general, it appears that invasive tumour cells exhibit enhanced adhesion and migration on laminin compared to less aggressive tumour cells. For this reason, studies aimed at understanding changes in the expression and function of specific laminin receptors during tumour progression are essential for understanding tumour behaviour.

Cell adhesion to laminin, as well as other extracellular matrix proteins, is mediated primarily by integrins and non-integrins. Integrins are a family of adhesion receptors comprised of two non-covalently linked subunits termed α and β (3–6). To date, six different integrins ($\alpha 1 \beta 1$, $\alpha 2 \beta 1$, $\alpha 3 \beta 1$, $\alpha 6 \beta 1$, $\alpha 7 \beta 1$, $\alpha 6 \beta 4$) have been implicated as laminin receptors (7–10). However, the $\alpha 6 \beta 4$ integrin has received considerable attention from cancer biologists because it is expressed predominantly on epithelial and carcinoma cells (3, 4, 7, 11–19). In normal epithelium, the expression of $\alpha 6 \beta 4$ is concentrated along the basal cell surface, which is in contact with the basement membrane (8–10, 20–23). One of the hallmarks of carcinoma cells is loss of polarity of $\alpha 6 \beta 4$ expression. In these cells, a diffuse distribution of this integrin over the entire cell surface is often observed.

A key issue that has not been resolved is whether the expression of $\alpha 6 \beta 4$ increases in metastatic cells compared to either

normal epithelial cells or cells of primary tumours. The $\beta 4$ integrin was initially characterized in mice as a metastasis-associated antigen (24), because its expression in carcinoma cells correlated with metastatic potential. However, studies on human tumours have not yielded such clear-cut results. For example, conflicting results on $\alpha 6 \beta 4$ expression in colon carcinoma have been reported (11, 12). In one study (11), it was suggested that the expression of this integrin did not change significantly in carcinomas compared to normal colon, while others report a marked decrease in $\alpha 6 \beta 4$ expression in primary as well as metastatic tumours (12). Immunohistochemical examination of $\alpha 6 \beta 4$ in pancreatic carcinomas revealed no change in expression compared to normal glandular epithelium, but studies on pancreatic cell lines indicated a direct correlation between loss of $\alpha 6 \beta 4$ expression and loss of differentiation (13). Breast carcinomas have been reported to be negative for $\alpha 6 \beta 4$ expression (14). Adenocarcinomas and squamous cell carcinomas of the lung are reported to have preserved expression of $\alpha 6 \beta 4$, while small cell carcinomas are negative (15). Squamous cell carcinomas of the head and neck exhibit increased expression of the A9 antigen (16, 17), recently demonstrated to represent a common epitope on the $\beta 4$ subunit (18). Basal cell carcinomas of the skin have been shown to have strong $\alpha 6 \beta 4$ expression in the superficial portion of the tumour and less expression in the deeper portion of the tumour (19).

The complex picture that has emerged from the various studies on $\alpha 6 \beta 4$ expression in different cancers prompted us to initiate a careful analysis of expression of $\alpha 6 \beta 4$ in squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs) of the skin. In particular, we sought to determine whether differences in expression were related to the invasive and metastatic potential of these tumours.

MATERIAL AND METHODS

Source of tissue

Fresh tissue samples representing SCCs and BCCs were received from the Department of Plastic Surgery, Rigshospitalet, Denmark. After routine sampling for diagnostic purposes, rest tissue representing ten SCCs and ten BCCs, all of which included normal epidermis, was sampled and snap-frozen in liquid nitrogen. Five- μ m cryostat sections were fixed in acetone for 10 min at room temperature.

Immunohistochemistry

A three-step indirect peroxidase technique was used (25). The primary antibodies were rat IgG2b monoclonal anti-human $\alpha 6$ (cat. no. MAB1972, lot 280CCB3, Chemicon, Temecula, Canada) (8) and mouse IgG1 monoclonal anti-human $\beta 4$ (cat. no. MAB1964, lot 253TPC3, Chemicon, Temecula, Canada) (26). Sections were incubated with primary antibodies for 30 min. Primary antibodies were diluted in phosphate-buffered saline (100 mM sodiumphosphate, 154 mM NaCl,

pH 7.4) containing 0.1 % bovine serum albumin. Secondary antibodies were horseradish-peroxidase conjugated rabbit anti-rat immunoglobulin (cat. no. P162, Dakopatts, Glostrup, Denmark) and horseradish-peroxidase conjugated rabbit anti-mouse immunoglobulin (cat. no. P260, Dakopatts, Glostrup, Denmark), both incubated for 30 min. Tertiary antibodies were horseradish-peroxidase conjugated swine anti-rabbit immunoglobulin (cat. no. P217, Dakopatts, Glostrup, Denmark), incubated for 30 min. All incubations were performed at room temperature and sections were rinsed with Tris-buffered saline (5 mM Tris-HCl, 147 mM NaCl, pH 7.6) between each step. Finally, sections were incubated for 10 min with freshly prepared substrate solution consisting of 0.04% ethyl-carbazole and 0.02% hydrogen peroxide in a sodium-acetate buffer (15 mM acetic acid, 35 mM sodium-acetate, pH 5.0), washed in distilled water, counterstained with Mayer's haematoxylin, and mounted in Kayser's glycerol-gelatine. Each immunohistochemical staining was performed three times to ensure reproducibility.

Controls included 1) replacing the primary antibody with antibodies of the same isotype as the primary ones, rat IgG2b (cat. no. 1118 129, lot 12539722-02, Boehringer Mannheim, Mannheim, Germany) and mouse IgG1 (cat. no. M724, lot 050, Dakopatts, Glostrup, Denmark), respectively; 2) deletion of primary antibodies; 3) deletion of primary and secondary antibodies; and 4) deletion of all antibodies.

RESULTS

In all sections both normal epidermis and tumour tissue were represented. The immunohistochemical expression of $\alpha 6$ and $\beta 4$ in tumour cells was compared to the expression in normal epidermis.

The $\alpha 6$ subunit

In normal epidermis and in adnex structures only the basal cells expressed $\alpha 6$ (Fig. 1A). The expression was associated to the cell membrane, with a linear accentuation along the epithelial-stromal interface. A less constant and weaker expression was seen at the lateral and apical surface of the basal keratinocytes. Perineural and endothelial cells were positive, with the endothelial cells showing strongest immunoreactivity in small blood vessels.

All ten cases of SCCs showed an increased expression of $\alpha 6$. The immunoreactivity was strongest in the cells at the periphery of the tumour islands and equally strong all around the cells (Fig. 2A). Thus, both increased intensity and change of expression pattern with depolarization of $\alpha 6$ expression were observed. Some of the squamous cell carcinomas showed an additional slight cytoplasmic positivity of the tumour cells. In one SCC, serial sectioning revealed tumour cell invasion into a small blood vessel (Fig. 3). These invasive keratinocytes exhibited a strong $\alpha 6$ immunoreactivity. In two cases of SCCs scattered positive lymphocytes were seen.

The tumour cells of the ten BCCs consistently showed a weak and clearly reduced intensity of $\alpha 6$ immunoreactivity as compared to normal epidermis (Fig. 2B). The staining pattern of the BCCs was generally similar to that of normal epidermis, with a polarization of the positivity along the epithelial-stromal interface. When BCCs were ulcerated an apparently stronger reaction could be seen in tumour cells adjacent to the ulcerated surface. However, when the surface was not ulcerated, the down-regulation of $\alpha 6$ expression was uniform in all portions of the tumours. All controls were negative.




Fig. 1. Immunostaining of normal epidermis with monoclonal antibodies to $\alpha 6$ and $\beta 4$. (A) $\alpha 6$ is expressed by basal cells and its expression is concentrated along the epithelial-stromal interface. A weaker and less constant expression is seen along the lateral and apical surface of the basal cells (laser scan microscope $\times 310$). (B) $\beta 4$ expression is similar to that of $\alpha 6$. A strong expression along the epithelial-stromal interface is seen and occasionally a weak expression along the lateral and apical surface of the basal cells (laser scan microscope $\times 500$).

The $\beta 4$ subunit

The staining pattern of $\beta 4$ closely resembled the pattern of $\alpha 6$. In the normal epithelium a reaction was seen in the basal cells (Fig. 1B). The reaction was strongest at the epithelial-stromal interface. Also a weak expression along the lateral and apical surface of the basal keratinocytes was occasionally seen. Perineural and endothelial cells were positive, paralleling the pattern of the $\alpha 6$ staining. The $\alpha 6$ -positive lymphocytes in two cases of SCCs were negative for $\beta 4$.

The $\beta 4$ staining of SCCs and BCCs closely paralleled the staining with $\alpha 6$ (Fig. 2C, D). Thus, SCCs showed an increased intensity and loss of polarization of $\beta 4$, while BCCs showed a decreased expression. In cases of ulceration, the $\beta 4$ expression pattern was similar to that of $\alpha 6$. However, as with the $\alpha 6$ staining, when the surface was not ulcerated the down-regulation of $\beta 4$ expression was uniform in all portions of the tumours (Figs. 2D and 4). All controls were negative.




Fig. 2. Immunostaining of SCC and BCC with monoclonal antibodies to $\alpha 6$ and $\beta 4$. (A) $\alpha 6$ expression in SCC cells is increased and its localization is depolarized compared to normal epidermis (arrow) (laser scan microscope $\times 270$). (B) $\alpha 6$ expression in BCC cells is significantly reduced ($\times 70$). (C) $\beta 4$ expression in SCC cells of the invasive front. The expression of $\beta 4$ by the peripheral tumour cells is increased and its localization is depolarized ($\times 170$). (D) $\beta 4$ expression in BCC cells of the invasive front. Its expression is significantly reduced ($\times 170$).

DISCUSSION

In the epidermis, the $\alpha 6$ integrin subunit associates primarily and probably exclusively with the $\beta 4$ integrin subunit (20–23). This pattern of integrin association is probably retained in tumours derived from epidermal cells. Thus, immunohistochemical studies using monoclonal antibodies to either the $\alpha 6$ or the $\beta 4$ subunit reflect expression of the $\alpha 6 \beta 4$ integrin heterodimer. The immunohistochemical results obtained in this study confirm this observation, because the staining patterns obtained with $\alpha 6$ and $\beta 4$ specific antibodies were identical. More importantly, the results obtained indicate a clear distinction between BCCs and SCCs in their expression of the $\alpha 6 \beta 4$ integrin. The ten BCCs examined exhibited a significant decrease in their expression of this integrin as compared to normal epidermis. In contrast, a marked increase in the intensity of $\alpha 6$ and $\beta 4$ staining was observed in the SCCs compared to normal epidermis. Also, SCCs were characterized by a depolarization of $\alpha 6 \beta 4$ expression compared to the basal surface polarization seen in normal epidermis. Because SCCs are, in general, more invasive and metastatic than BCCs, the possibility exists that increased $\alpha 6 \beta 4$

expression and loss of its basal polarity are related to tumour invasion and metastasis (Fig. 3).

The expression of the $\alpha 6 \beta 4$ integrin has been shown to increase during the malignant conversion of mouse epidermal keratinocytes (27). In humans, $\beta 4$ expression has been shown to increase during the neoplastic progression of intraepithelial neoplasias of the cervix uteri (28). In human SCCs (16, 17), expression of the $\alpha 6 \beta 4$ integrin has been examined with the UM-A9 monoclonal antibody which recognizes the $\beta 4$ integrin subunit (18). These studies, as well as our results, show that SCCs exhibit alterations in the polarity and intensity of the $\alpha 6 \beta 4$ expression. Moreover, A9 antigen expression has been used to predict the clinical outcome of SCCs of the head and neck. Tumours that most strongly expressed this antigen had a higher incidence of recurrence (17).

In a study by Sollberg et al. (19), which included six BCCs, it was shown that superficial portions of BCCs had a strong expression of $\beta 4$ while the deeper portions were less positive. Furthermore, it was found that the lateral surface of the peripheral tumour cells in the BCCs was occasionally positive, a phenomenon that was not seen in normal epidermis. These




Fig. 3. Immunostaining of SCC with monoclonal antibodies to $\alpha 6$, serial sections (A&B). (B) Tumour cell invasion of a small blood vessel is observed. The invading cells exhibit a strong expression and depolarized localization of $\alpha 6$ (A: $\times 150$, B: $\times 130$).

results differ somewhat from ours. First, we did not find a significant difference of $\alpha 6\beta 4$ expression within different portions of the BCCs (Figs 2D and 4). Only when the surface of the BCCs was ulcerated could a somewhat stronger expression be seen in the superficial portion. The phenomenon of an increased expression in these cases might represent some kind of reaction to the ulceration. Thus we do not find it possible to draw conclusions about invasive properties of superficial versus profound tumour cells in BCCs based on these observations. Second, a weak $\beta 4$ expression along the lateral and apical surface of normal basal keratinocytes was occasionally seen in our preparations (Fig. 1). In other studies of $\beta 4$ expression in normal squamous epithelium this detail has not always been clarified. Some results indicate that $\beta 4$ is only expressed along the epithelial-stromal interface (29), while others support our results (30).

In an *in vitro* model of wound healing Kurpakus et al. (31) have shown that in keratinocytes migrating from the edges of a wound over bare connective tissue $\alpha 6\beta 4$ appears along the entire cell surface. Only at a later stage, as cells become positive for cytosolic hemidesmosome compounds, the $\alpha 6\beta 4$ is concen-




Fig. 4. Immunostaining of BCC with monoclonal antibodies to $\beta 4$. The superficial non-ulcerated area of BCC exhibits the same staining pattern as the deep, invasive portion of the same tumour (Fig. 2D) ($\times 170$).

trated along the basal pole of the cell. These results indicate that basal keratinocytes are able to regulate the polarization of $\alpha 6\beta 4$ integrin expression. The same events that determine the depolarization of $\alpha 6\beta 4$ integrin in migrating keratinocytes of wound healing could very well be responsible for the depolarization of $\alpha 6\beta 4$ expression in SCCs. This hypothesis raises a question for future investigation: is depolarization of $\alpha 6\beta 4$ integrin on SCCs an event that contributes to the invasive properties of the SCC cells or is it a "normal physiological response" to the cell-stromal interactions of the invasive growing SCC cells?

It is tempting to interpret the striking difference in expression of $\alpha 6\beta 4$ integrin by SCCs and BCCs as being related to the difference in invasive and metastatic behaviour of the two tumour types. Yet, it must be remembered that even though SCCs and BCCs originate from the same epithelium the phenotypes of the two tumour types are very different, a circumstance that makes conclusions drawn from such a comparison uncertain. Even so, our results in combination with other studies suggest that in SCCs the increase in expression of $\alpha 6\beta 4$ integrin may be related to invasion. Furthermore it is possible that the depolarization of $\alpha 6\beta 4$ in SCCs may promote migrative/invasive properties. However, we do not find that this assumption necessarily implies that the loss of $\alpha 6\beta 4$ expression seen in BCCs is functionally related to the low metastatic potential of this tumour.

ACKNOWLEDGEMENT

These studies were supported by the Danish Cancer Research Council and a NATO Collaborative Research Grant.

REFERENCES

1. Wewer UM, Liotta LA, Jaye M, Ricca GA, Drohan WN, Clay Smith AP, et al. Altered levels of laminin receptor mRNA in various human carcinoma cells that have different abilities to bind laminin. *Proc Natl Acad Sci USA* 1986; 83: 7137-7141.
2. Liotta LA, Rao CN, Wewer U. Biochemical interaction of tumor

- cells with the basement membrane. *Ann Rev Biochem* 1986; 55: 1037–1057.
3. Hynes RO. Integrins: versatility, modulation, and signalling in cell adhesion. *Cell* 1992; 69: 11–25.
 4. Humphries MJ. The molecular basis and specificity of integrin-ligand interactions. *J Cell Sci* 1990; 97: 585–592.
 5. Ruoslahti E, Giancotti FG. Integrins and tumor cell dissemination. *Cancer Cells* 1989; 1: 119–125.
 6. Virtanen I, Korhonen M, Kariniemi A-L, Gould VE, Laitinen L, Ylännä J. Integrins in human cells and tumors. *Cell Diff Develop* 1990; 32: 215–228.
 7. Mercurio AM, Shaw LM. Laminin binding proteins. *BioEssays* 1991; 13: 469–473.
 8. Hemler ME, Crouse C, Sonnenberg A. Association of the VLA $\alpha 6$ subunit with a novel protein. *J Biol Chem* 1989; 264: 6529–6535.
 9. Kajiji S, Tamura RN, Quaranta V. A novel integrin ($\alpha E\beta 4$) from human epithelial cells suggest a fourth family of integrin adhesion receptors. *EMBO J* 1989; 8: 673–680.
 10. Tamura RN, Rozzo C, Starr L, Chambers J, Reichardt LF, Cooper HM, et al. Epithelial integrin $\alpha 6\beta 4$: complete primary structure of $\alpha 6$ and variant forms of $\beta 4$. *J Cell Biol* 1990; 111: 1593–1604.
 11. Lee EC, Lotz MM, Steele GD, Mercurio AM. The integrin $\alpha 6\beta 4$ is a laminin receptor. *J Cell Biol* 1992; 117: 671–678.
 12. Stallmach A, v Lampe B, Matthes H, Bornhöft G, Riecken EO. Diminished expression of integrin adhesion molecules on human colonic epithelial cells during the benign to malign tumour transformation. *Gut* 1992; 33: 342–346.
 13. Hall PA, Coates P, Lemoine NR, Hortons MA. Characterization of integrin chains in normal and neoplastic human pancreas. *J Pathology* 1991; 165: 33–41.
 14. Koukoulis GK, Virtanen I, Korhonen M, Laitinen L, Quaranta V, Gould V. Immunohistochemical localization of integrins in normal, hyperplastic, and neoplastic breast. *Am J Path* 1991; 139: 787–799.
 15. Costantini RM, Falcioni R, Battista P, Zupi G, Kennel SJ, Colasante A, et al. Integrin ($\alpha 6\beta 4$) expression in human lung cancer as monitored by specific monoclonal antibodies. *Cancer Res* 1990; 50: 6107–6112.
 16. Kimmel KA, Carey TE. Altered expression in squamous cell carcinoma cells of an orientation restricted epithelial antigen detected by monoclonal antibody A9. *Cancer Res* 1986; 46: 3614–3623.
 17. Wolf GT, Carey TE, Schmaltz SP, McClatchey KD, Poore J, Glaser L, et al. Altered antigen expression predict outcome in squamous cell carcinoma of the head and neck. *J Natl Cancer Inst* 1990; 82: 1566–1572.
 18. Van Waes C, Kozarsky KF, Warren AB, Kidd L, Paugh D, Liebert M, et al. The A9 antigen associated with aggressive human squamous cell carcinoma is structurally and functionally similar to the newly defined integrin $\alpha 6\beta 4$. *Cancer Res* 1991; 51: 2395–2402.
 19. Sollberg S, Peltonen J, Uitto J. Differential expression of laminin isoforms and $\beta 4$ integrin epitopes in the basement membrane zone of normal human skin and basal cell carcinomas. *J Invest Dermatol* 1992; 98: 864–870.
 20. Eberhard Klein C, Steinmayer T, Mattes JM, Kaufmann R, Weber L. Integrins of normal human epidermis: differential expression, synthesis and molecular structure. *Br J Dermatol* 1990; 123: 171–178.
 21. Stepp MA, Spurr-Michaud S, Tisdale A, Elwell J, Gipson IK. $\alpha 6\beta 4$ integrin is a component of hemidesmosomes. *Proc Natl Acad Sci USA* 1990; 87: 8970–8974.
 22. De Luca M, Tamura RN, Kajiji S, Bondanza S, Rossini P, Cancedda R, et al. Polarized integrin mediates human keratinocyte adhesion to basal lamina. *Proc Natl Acad Sci USA* 1990; 87: 6888–6892.
 23. Sonnenberg A, Calafat J, Janssen H, Daams H, van der Raaij-Helmer LMH, Falcioni R, et al. Integrin $\alpha 6\beta 4$ complex is located in hemidesmosomes, suggesting a major role in epidermal cell-basement membrane adhesion. *J Cell Biol* 1991; 113: 907–917.
 24. Falcioni R, Kennel SJ, Giacomini P, Zupi G, Sacchi A. Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice. *Cancer Res* 1986; 46: 5772–5778.
 25. Naish SJ. Immunohistochemical staining methods: In: Boenish T, ed. Staining methods. Carpinteria, California: DAKO Corporation 1989: 13–18.
 26. Hessle H, Sakai LY, Hollister DW, Burgeson RE, Engvall E. Basement membrane diversity detected by monoclonal antibodies. *Differentiation* 1984; 26: 49–54.
 27. Gomez M, Navarro P, Quintanilla M, Cano A. Expression of $\alpha 6\beta 4$ integrin increases during malignant conversion of mouse epidermal keratinocytes: association of $\beta 4$ subunit to the cytokeratin fraction. *Exp Cell Res* 1992; 201: 250–261.
 28. Carico EC, French D, Bucci B, Falcioni R, Vecchione A, Mariani-Constantini R. Integrin $\beta 4$ expression in the neoplastic progression of cervical epithelium. *Gyn Onc* 1993; 49: 61–66.
 29. Carter WG, Kaur P, Gil SG, Gahr PJ, Wayner EA. Distinct functions for integrin $\alpha 3\beta 1$ in focal adhesions and $\alpha 6\beta 4$ /bullous pemphigoid antigen in a stable anchoring contact (SAC) of keratinocytes: relation to hemidesmosomes. *J Cell Biol* 1990; 111: 3141–3154.
 30. Homia M, Virtanen I, Quaranta V. Immunolocalization of integrin $\alpha 6\beta 4$ in mouse junctional epithelium suggest an anchoring function to both the internal and external basal lamina. *J Dent Res* 1991; 71: 1503–1508.
 31. Kurpakus MA, Quaranta V, Jones JCR. Surface relocation of $\alpha 6\beta 4$ integrin and assembly of hemidesmosomes in an in vitro model of wound healing. *J Cell Biol* 1991; 115: 1737–1750.